1. Home
  2. UG vs GBIO Comparison

UG vs GBIO Comparison

Compare UG & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UG
  • GBIO
  • Stock Information
  • Founded
  • UG 1942
  • GBIO 2016
  • Country
  • UG United States
  • GBIO United States
  • Employees
  • UG N/A
  • GBIO N/A
  • Industry
  • UG Package Goods/Cosmetics
  • GBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • UG Consumer Discretionary
  • GBIO Health Care
  • Exchange
  • UG Nasdaq
  • GBIO Nasdaq
  • Market Cap
  • UG 36.4M
  • GBIO 41.2M
  • IPO Year
  • UG N/A
  • GBIO 2020
  • Fundamental
  • Price
  • UG $7.23
  • GBIO $5.40
  • Analyst Decision
  • UG
  • GBIO Buy
  • Analyst Count
  • UG 0
  • GBIO 4
  • Target Price
  • UG N/A
  • GBIO $10.67
  • AVG Volume (30 Days)
  • UG 6.4K
  • GBIO 47.7K
  • Earning Date
  • UG 11-11-2025
  • GBIO 11-07-2025
  • Dividend Yield
  • UG 9.59%
  • GBIO N/A
  • EPS Growth
  • UG N/A
  • GBIO N/A
  • EPS
  • UG 0.56
  • GBIO N/A
  • Revenue
  • UG $10,856,174.00
  • GBIO $21,230,000.00
  • Revenue This Year
  • UG N/A
  • GBIO N/A
  • Revenue Next Year
  • UG N/A
  • GBIO N/A
  • P/E Ratio
  • UG $13.12
  • GBIO N/A
  • Revenue Growth
  • UG N/A
  • GBIO 61.15
  • 52 Week Low
  • UG $7.25
  • GBIO $3.00
  • 52 Week High
  • UG $14.05
  • GBIO $25.70
  • Technical
  • Relative Strength Index (RSI)
  • UG 42.03
  • GBIO 36.65
  • Support Level
  • UG $7.36
  • GBIO $6.06
  • Resistance Level
  • UG $7.49
  • GBIO $6.47
  • Average True Range (ATR)
  • UG 0.15
  • GBIO 0.29
  • MACD
  • UG -0.00
  • GBIO -0.13
  • Stochastic Oscillator
  • UG 11.16
  • GBIO 8.97

About UG United-Guardian Inc.

United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: